Highlighted Data
Recent Clinical Data Presentations
ASRS 2021 — ADVM-022 Clinical Data
First Time Data from the INFINITY Trial of ADVM-022 Intravitreal Gene Therapy for DME
Retina Society 2021 — ADVM-022 Clinical Data
New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD – Cohorts 1-4
ARVO 2021 — ADVM-022 Clinical Data
New Clinical Data from OPTIC Phase 1 Trial of ADVM-022 in Wet AMD – Cohorts 1-4
Publications
Translational Vision Science & Technology
January 2021, Vol.10, 34
Long-Term Safety Evaluation of Continuous Intraocular Delivery of Aflibercept by the Intravitreal Gene Therapy Candidate ADVM-022 in Nonhuman Primates
Molecular Therapy – Methods & Clinical Development
Volume 18, Page 345-353
Analysis of aflibercept expression in non-human primates following intravitreal administration of ADVM-022, a potential gene therapy for neovascular age-related macular degeneration
ADVM-022 Clinical Data
Clinical Data Presentations
ASRS 2021
Encore Data from OPTIC Phase 1 Trial of ADVM-022 in Wet AMD – Cohorts 1-4
ASRS 2021
First Time Data from the INFINITY Trial of ADVM-022 Intravitreal Gene Therapy for DME
Retina Society 2021
New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD – Cohorts 1-4
ASGCT 2021
Encore Data from OPTIC Phase 1 Trial of ADVM-022 in Wet AMD – Cohorts 1-4
ARVO 2021
New Clinical Data from OPTIC Phase 1 Trial of ADVM-022 in Wet AMD – Cohorts 1-4
Angiogenesis 2021
Encore Data from OPTIC Phase 1 Trial of ADVM-022 in Wet AMD – Cohorts 1-4
KOL/IR Discussion around AAO 2020
New Clinical Data from OPTIC Phase 1 Trial of ADVM-022 in Wet AMD – Cohorts 1-4
KOL/IR Discussion for 2Q20
New Clinical Data from OPTIC Phase 1 Trial of ADVM-022 in Wet AMD – Cohorts 1-4
KOL/IR Discussion around ARVO 2020
New Clinical Data from OPTIC Phase 1 Trial of ADVM-022 in Wet AMD – Cohorts 1-3
Angiogenesis, Exudation, and Degeneration Annual Meeting 2020
New Clinical Data from OPTIC Phase 1 Trial of ADVM-022 in Wet AMD – Cohorts 1&2
Atlantic Coast Retina Club Macula 20/20 Annual Meeting
New Clinical Data from OPTIC Phase 1 Trial of ADVM-022 in Wet AMD – Cohort 1
American Academy of Ophthalmology Annual Meeting 2019
New Clinical Data from OPTIC Phase 1 Trial of ADVM-022 in Wet AMD – Cohort 1
Retina Society Annual Meeting 2019
New Clinical Data from OPTIC Phase 1 Trial of ADVM-022 in Wet AMD – Cohort 1
ADVM-022 Preclinical Data
Preclinical Data Presentations
ARVO Annual Meeting 2019
Immunological response and durability of expression following sequential intravitreal administration of AAV2.7m8 gene therapy to the contralateral eye in non-human primates
Angiogenesis, Exudation, and Degeneration Annual Meeting 2019
Gene Therapy for Neovascular AMD: Intravitreal Delivery of AAV-7m8 vectors
ASGCT Annual Meeting 2018
AAV.7m8-aflibercept Provides Long-term Protection in a Non-human Primate Model of Wet Macular Degeneration Over One Year Post Intravitreal Vector Administration
Preclinical Data Publications
Translational Vision Science & Technology
January 2021, Vol.10, 34
Long-Term Safety Evaluation of Continuous Intraocular Delivery of Aflibercept by the Intravitreal Gene Therapy Candidate ADVM-022 in Nonhuman Primates
Molecular Therapy – Methods & Clinical Development
Volume 18, Page 345-353
Analysis of aflibercept expression in non-human primates following intravitreal administration of ADVM-022, a potential gene therapy for neovascular age-related macular degeneration
Molecular Therapy
Volume 27, Issue 1, Pages 118-129
Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration
Additional Research Presentations
Presentations and Posters
ARVO Annual Meeting 2021
Preclinical Evaluation of ADVM-062, a Novel Intravitreal Gene Therapy for the Treatment of Blue Cone Monochromacy
ARVO Annual Meeting 2020
Intravitreal Delivery of AAV2.7m8. Ranibizumab Suppresses Exudative Lesions in the NHP Laser Induced Model of nAMD
ARVO Annual Meeting 2020
Mouse Studies Support Intravitreal Gene Therapy for Blue Cone Monochromacy
ASGCT Virtual Annual Meeting 2020
Proof-of-Concept Studies in Mongolian Gerbils Support Intravitreal Gene Replacement Therapy of Human L-Opsin for Blue Cone Monochromacy
ASGCT Virtual Annual Meeting 2020
Large Scale Suspension Production of AAV Capsid Variant Libraries from Stable Recombinant HEK293 Cell Banks
ESGCT Annual Meeting 2019
In vivo screening of an adeno-associated virus capsid library in nonhuman primate eyes identifies a novel AAV variant with superior retinal penetration and transduction by intravitreal delivery
ESGCT Annual Meeting 2019
Biodistribution and pharmacokinetics of AAVRh.10-A1AT mediated gene therapy in humanized-liver mice as a predictor of A1AT human expression levels following intravenous delivery
ESGCT Annual Meeting 2019
Feasibility of Gene Therapy for Friedreich Ataxia Associated Cardiomyopathy in Non-Human Primates: Evaluation of Delivery Route, Biodistribution and Expression Following AAVRh.10-hFXN Administration
ARVO Annual Meeting 2018
Long-term functional delivery of the human L-opsin cDNA via intravitreal administration of an AAV vector in Mongolian gerbils
ARVO Annual Meeting 2017
Assessment of next-generation AAV variants in gerbil and non-human primate retina following intravitreal injection
ASGCT Annual Meeting 2017
Analysis of gene expression, tissue tropism, and safety of novel AAV variants in mice following intravenous administration